. 2017 Dec 9;8(69):113472–113493. doi: 10.18632/oncotarget.23052

Table 1. VEGF-A and MMP-9 secretion in A375 and SK-Mel28 cell lines and their dabrafenib-resistant counterparts.

Cell Line	VEGF-A (ng/10⁶ cells)^a			MMP-9 (pg/10⁶ cells)^a
Cell Line	DMSO^b	Dabrafenib^b	P^c	DMSO^b	Dabrafenib^b	P^c
SK-Mel28	1.48 ± 0.13	0.50 ± 0.06	<0.01	5.15 ± 0.64	0.50 ± 0.07	<0.01
SK-Mel28R	76.00 ± 7.61^**	82.98 ± 9.38^**	NS	83.75 ± 9.91^**	95.75 ± 16.82^**	NS
A375 (ref. 31)	7.48 ± 1.27	3.50 ± 0.98	<0.05	24.25 ± 2.10	24.75 ± 6.52	NS
A375R (ref. 31)	15.83 ± 1.47^**	26.04 ± 2.66^**	<0.05	47.88 ± 3.79^**	75.75 ± 4.09^**	<0.01

^aThe amount of VEGF-A and MMP-9 in cell culture supernatants was determined by ELISA.

^bcells were cultured with 100 nM dabrafenib or DMSO alone for 48 h and then culture supernatants were collected and assayed for VEGF-A and MMP-9 content.

^cP, probability calculated according to Student’s t-test comparing dabrafenib-treated with DMSO-treated cells.

^**P < 0.01 comparing A375R cells with A375 cells, and SK-Mel28R cells with SK-Mel28 cells.